Universal Cells

Making stem cells compatible with everyone

Editing the genome without breaking it

Therapeutic genome editing 

Universal Cells is a therapeutic genome editing company. The company uses a nuclease-free technology platform for efficient and accurate editing of any chromosomal gene, without off-target cutting.

Universal Cells is developing HLA-engineered Universal Donor Cells that are off-the-shelf stem cell products compatible with everyone. No immune suppression. No donor matching. No rejection.

In addition, the company is developing therapeutics that target and correct the underlying genetic causes of diseases.

Our approach

Universal Cells patented technology is based on recombinant adeno-associated virus (rAAV)-mediated gene editing, which offers high accuracy and safety, and the best vehicle available for cellular delivery.

  • Nuclease free: no genotoxicity or off-target cutting
  • Optimized delivery for stem cells
  • Controlled transgene integration
  • Clinically validated vectors
aav_diagram_generic.png

Recombinant adeno-associated virus (rAAV) vectors are single-stranded DNA vectors that efficiently infect stem cells and edit the genome by homologous recombination. The rAAV genome (green) is engineered to contain DNA sequences homologous to a chromosomal target gene (blue arrows). The rAAV sequence can include mutations to knockout gene expression or knock-in new genes of interest (red). 

Latest News

Dec 1, 2015, 10:02 PM
Universal Cells enters collaboration with Adaptimmune.
Sep 21, 2015, 10:02 PM
We will be attending the 2015 Stem Cell Meeting on the Mesa in San Diego from October 7-9th. Please contact us through the meeting partnering system to schedule time to meet with us.
Oct 30, 2014, 6:00 PM
Dr. David Russell was the 2014 University of Washington inventor of the year.
Jan 2, 2014, 6:00 PM
Universal Cells has recently been awarded a phase II SBIR grant to expand our research program.
Jul 3, 2014, 10:00 PM
We have recently announced the closure of a $300,000 angel round of investment.